✦ LIBER ✦

883 POSTER Phase I trial of sorafenib (BAY 43–9006) in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma

Book ID: 118623459
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 140 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(05)81178-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

795 ORAL Phase II trial of sorafenib (BA

795 ORAL Phase II trial of sorafenib (BAY 43–9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 273 KB

Phase I trial of sorafenib in combinatio

Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

✍ Masashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, Hirofumi Fujii, Yasuo Ham 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 359 KB

Erratum to: Phase I trial of sorafenib i

Erratum to: Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma

✍ Masashi Niwakawa, Katsuyoshi Hashine, Raizo Yamaguchi, Hirofumi Fujii, Yasuo Ham 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 65 KB

A clinical phase I/II trial with the mon

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

✍ M. Siebels; K. Rohrmann; R. Oberneder; M. Stahler; N. Haseke; J. Beck; R. Hofman 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 311 KB

995 ORAL A phase II trial of BAY 43–9006

995 ORAL A phase II trial of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). a Southwest Oncology Group (SWOG) trial

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 137 KB

A phase I study of recombinant human int

A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma

✍ A. Mittelman; M. Huberman; C. Puccio; B. Fallon; J. Tessitore; S. Savona; R. Eyr 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 662 KB

Preclinical data suggest synergy of interleukin-2 (IL-2) combined with alphainterferon (IFN). In addition, toxicities of IL-2 may be decreased by intermittent continuous infusion. The purpose of this trial was to determine the maximum tolerated dose (MTD) of recombinant IL-2 combined with alpha-IFN